Key result
Clevidipine hits target SBP in ~6 minutes in acute ICH without altering most BP variability measures.
Why the study?
Although rapid blood pressure lowering is recommended after spontaneous intracerebral hemorrhage, the physiologic effects of clevidipine on high-frequency systolic blood pressure variability remain incompletely characterized.
Does continuous intravenous clevidipine infusion provide rapid blood pressure control and minimize systolic blood pressure variability in adults presenting with acute hypertensive spontaneous intracerebral hemorrhage?
Observational (n=20)
Open-label
No
Does continuous intravenous clevidipine infusion provide rapid blood pressure control and minimize systolic blood pressure variability in adults presenting with acute hypertensive spontaneous intracerebral hemorrhage?
In patients with acute hypertensive intracerebral hemorrhage, continuous clevidipine infusion rapidly achieves and maintains target systolic blood pressure within minutes with minimal clinically significant hypotension and without worsening absolute short-term blood pressure variability.
Answers are grounded in this paper and cite their sources.
May support rapid SBP control in acute ICH with limited variability impact; hypothesis-generating and should not yet change practice.
Background Acute systolic hypertension after spontaneous intracerebral hemorrhage (ICH) is associated with hematoma expansion and worse outcomes. Although rapid blood pressure lowering is recommended, the physiologic effects of clevidipine on high-frequency systolic blood pressure variability (BPV) in acute ICH remain incompletely characterized. Methods We conducted a single-center, prospective, open-label observational study of adults with spontaneous supratentorial ICH presenting within 12 hours of last known well who required continuous intravenous antihypertensive therapy. Clevidipine was initiated at 1 mg/hour and titrated to a target systolic blood pressure (SBP) of 130–160 mmHg. Beat-to-beat arterial SBP was recorded at 300 Hz after neurointensive care unit admission. Primary outcomes were descriptive measures of BPV before and after clevidipine initiation, including standard deviation, average real variability (ARV), and coefficient of variation (CV). Secondary outcomes included time to target SBP, time to control with stability, hematoma expansion, neurologic deterioration, hypotension exposure, and in-hospital mortality. Results Twenty patients were enrolled between March 2022 and February 2025. Mean age was 57.8 ± 15.4 years, 60% were female, and 70% were Black/African American. Median peak pre-enrollment SBP was 193.5 mmHg. Median time to achieve SBP 130–160 mmHg was 5.9 minutes (IQR 0.6–10.2), and median time to control with stability was 6.3 minutes (IQR 1.7–14.2). Patients remained within target SBP for a median 73.7% of infusion time. Relative hypotension (SBP < 130 mmHg) occurred during 9.6% of infusion time, whereas absolute hypotension (SBP < 90 mmHg) was rare (0.05%). Mean SBP decreased from 169.5 mmHg before infusion to 151.9 mmHg in the first hour and remained controlled through 12 hours. Standard deviation and ARV did not significantly change after clevidipine initiation, while CV increased modestly (7.1% vs 9.9%, p = 0.037). Hematoma expansion occurred in 30% and in-hospital mortality was 20%. Conclusions In acute spontaneous ICH, clevidipine provided rapid, sustained SBP control with minimal clinically significant hypotension and no clear increase in absolute short-term BPV. These findings support its feasibility and safety for intensive hyperacute blood pressure management.
No takes yet. Share an insight, caveat, or question.
Hassett et al. (2026) conducted an observational in Hypertensive acute spontaneous intracerebral hemorrhage (n=20). Clevidipine vs. Baseline (prior to clevidipine initiation) was evaluated on Systolic blood pressure variability (Coefficient of variation [%], Standard deviation [mmHg], and Average real variability [mmHg]) within the first hour after clevidipine initiation vs baseline (p=0.037). Clevidipine achieved target SBP in a median of 5.9 minutes in acute ICH patients without changing SBP standard deviation or average real variability, though CV increased.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: